Previous studies in murine prostate cancer models have demonstrated that CTLA-4 blockade promotes anti-tumor activity [17] and works synergistically with GM-CSF-expressing tumor vaccines [18]. This evidence concerns the gene CSF2 and prostate carcinoma.